Global Low Molecular Weight Heparin Market is Projected to Reach 22.1 tonne by 2023

This report studies the Low Molecular Weight Heparin market, Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.

Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.

The global consumption of low molecular weight heparin increases from 12.47 tonne in 2012 to 16.85 tonne in 2016, at a CAGR of more than 7.82%. In 2016, in term of volume, the global Low molecular weight heparin market is led by Europe, capturing about 35.25% of global low molecular weight heparin consumption. USA is the second’s largest market with the share of 33.08%.

China is a big low molecular weight heparin production country, especially Heparin API, but it is not strong country. According to our research and analysis, manufacturers from United States and Europe are the major leaders in the international market of low molecular weight heparin. Manufacturers from China are immature in technology. There is large space in the China market, as well as big gap between international brands and local brands on price.


The leading companies own the advantages on better performance, more abundant product’s types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market. Looking to the future years, the slow upward price trend in recent years will maintain. As competition intensifies, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.

The industry is expected to remain innovation-led, with frequent acquisitions and strategic alliances adopted as the key strategies by the players to increase their industry presence. Market stays in mature period with a clear concentration. Meanwhile, optimize product mix and further develop value-added capabilities to maximize margins.

The Global Low Molecular Weight Heparin Market Research Report 2018 report released by QYResearch provides a basic overview of the Low Molecular Weight Heparin industry, including definition, classification, application and industrial chain structure. Discuss development policies and plans as well as manufacturing processes and cost structures.

The report then focuses on major industry players in Global, including company profiles, product images and specifications, sales, market share, and contact information. More importantly, the Low Molecular Weight Heparin industry development trends and marketing channels were analyzed. Providing the main statistical data on the current status of the industry is a valuable guide and direction for companies and individuals interested in the market.

Market Segment by Regions, regional analysis covers
USA
China
Europe
Asia (Ex. China)
Market Segment Applications, can be divided into
Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Others
Market Segment by Type, covers
Enoxaparin
Dalteparin
Tinzaparin
Fraxiparine
Low Molecular Weight Heparin Competitive landscape and key vendors
Aspen
Sanofi-aventis
Pfizer
Opocrin
CSBIO
Dongying Tiandong Pharmaceutical
Changzhou Qianhong Bio-pharma
Techdow
Yantai Dongcheng Pharmaceutical Group


About Us: QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.